OAM
BDTX icon

Oxford Asset Management’s Black Diamond Therapeutics BDTX Stock Holding History

Oxford Asset Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,083
Closed -$49.2K – 396
2026
Q1 		$49.2K Sell
23,083
-91,300
-80% -$217K 0.02% 450
2025
Q4 		$278K Buy
+114,383
New +$405K 0.1% 321
2020
Q1 		$1.96M Buy
+78,385
New +$2.39M 0.28% 73

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Oxford Asset Management's BDTX Position: Q2 2026 in Review

Oxford Asset Management sold out of Black Diamond Therapeutics (BDTX) in Q2 2026, closing a stake of 23,083 shares — an estimated $49.2K sold.

Oxford Asset Management first reported a position in BDTX in Q1 2020 and held it in 3 quarters. The position peaked at $1.96M in Q1 2020. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Oxford Asset Management reported no remaining Black Diamond Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Oxford Asset Management sold 23,083 Black Diamond Therapeutics shares in Q2 2026, an estimated $49.2K.
  • Oxford Asset Management first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 3 quarters.
  • Oxford Asset Management's Black Diamond Therapeutics position peaked at $1.96M in Q1 2020.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.